Status:
RECRUITING
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Head and Neck Tumors
Kidney Cancers
Eligibility:
All Genders
18-120 years
Phase:
PHASE1
Brief Summary
Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and...
Detailed Description
Background: * Somatostatin receptors (SSTR) have been shown to be over-expressed in a number of human tumors, including gastrointestinal (GI) neuroendocrine tumors (NET), pheochromocytoma/paraganglio...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
August 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2032
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06479811
Start Date
August 19 2025
End Date
January 1 2032
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892